Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
DC CAFCFirst Claim
Patent Images
1. An isolated human monoclonal antibody that binds to an epitope on PSCK9, wherein the epitope comprises at least one of amino acid residues S123, E129, A311, D313, or D337 of SEQ ID NO:
- 1, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR.
1 Assignment
Litigations
0 Petitions
Accused Products
Abstract
Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
-
Citations
25 Claims
-
1. An isolated human monoclonal antibody that binds to an epitope on PSCK9, wherein the epitope comprises at least one of amino acid residues S123, E129, A311, D313, or D337 of SEQ ID NO:
- 1, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
-
16. An isolated human monoclonal antibody that binds to human PCSK9 having an amino acid sequence of SEQ ID NO:
- 1 at one or more of amino acid residues S123, E129, A311, D313, or D337 of SEQ ID NO;
1, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR. - View Dependent Claims (17, 18, 19, 20, 21, 22, 23, 24, 25)
- 1 at one or more of amino acid residues S123, E129, A311, D313, or D337 of SEQ ID NO;
Specification